Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study

Lunit SCOPE Reveals HER2 Expression Differences Linked to Treatment Response Beyond Conventional Testing in Nature Medicine Study

AI-powered whole-slide analysis provides insights into treatment response beyond conventional HER2 classification SEOUL, South Korea, Oct. 14, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision...

menu
menu